“…one large, well-designed study found remdesivir modestly reduced the time to recover from COVID-19 in hospitalized patients with severe illness. A few smaller studies found no impact of treatment on the disease whatsoever. Then, on 15 October… the fourth and largest controlled study delivered what some believed was a coup de grâce: The World Health Organization’s (WHO’s) Solidarity trial showed that remdesivir does not reduce mortality or the time COVID-19 patients take to recover.”

“…on 22 October, the U.S. Food and Drug Administration (FDA) approved remdesivir for use against the pandemic coronavirus SARS-CoV-2 in the United States—the first drug to receive that status.”

“In late August it noted a disproportionately high number of reports of liver and kidney problems in patients receiving remdesivir compared with patients receiving other drugs for COVID-19.”

“FDA never consulted a group of outside experts that it has at the ready to weigh in on complicated antiviral drug issues.”

Source: Science

Share on facebook
Share on telegram
Share on twitter
Share on email

CDC’s definition of “unvaccinated” includes individuals which have received a vaccine:

“Persons were considered fully vaccinated ≥14 days after receipt of the second dose in a 2-dose series (Pfizer-BioNTech or Moderna COVID-19 vaccines) or after 1 dose of the single-dose Janssen (Johnson & Johnson) COVID-19 vaccine; partially vaccinated ≥14 days after receipt of the first dose and <14 days after the second dose in a 2-dose series; and unvaccinated <14 days after receipt of the first dose of a 2-dose series or 1 dose of the single-dose vaccine or if no CAIR2 vaccination data were available.” [Emphasis mine.]

“COVID-19–associated hospitalizations were defined as hospital admissions occurring ≤14 days after a first SARS-CoV-2 infection. COVID-19–associated deaths were defined as deaths occurring ≤60 days after the date of a first laboratory-confirmed SARS-CoV-2 infection or deaths with COVID-19 listed as a cause of or contributing condition to death.”

Source: CDC

Share on facebook
Share on telegram
Share on twitter
Share on email

“We conducted a retrospective observational study comparing three groups: (1)SARS-CoV-2-naïve individuals who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, (2)previously infected individuals who have not been vaccinated, and (3)previously infected and single dose vaccinated individuals.”

“SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected…”

“The increased risk was significant (P<0.001) for symptomatic disease as well.”

“SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected.”

“This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.”

This study was conducted by research scientists and medical professionals in Tel Aviv, Israel.

Source: MedRxiv

Share on facebook
Share on telegram
Share on twitter
Share on email

“Infection-enhancing antibodies have been detected in symptomatic Covid-19. Antibody dependent enhancement (ADE) is a potential concern for vaccines.”

“…in the case of the Delta variant, neutralizing antibodies have a decreased affinity for the spike protein, whereas facilitating antibodies display a strikingly increased affinity. Thus, ADE may be a concern for people receiving vaccines based on the original Wuhan strain spike sequence…”

“ADE may occur in people receiving vaccines based on the original Wuhan strain spike sequence (either mRNA or viral vectors) and then exposed to a Delta variant. Although this potential risk has been cleverly anticipated before the massive use of Covid-19 vaccines, the ability of SARS-CoV-2 antibodies to mediate infection enhancement in vivo has never been formally demonstrated.”

Source: Journal of Infection

Share on facebook
Share on telegram
Share on twitter
Share on email

“My research team at Johns Hopkins worked with the nonprofit FAIR Health to analyze approximately 48,000 children under 18 diagnosed with Covid in health-insurance data from April to August 2020.

Our report found a mortality rate of zero among children without a pre-existing medical condition such as leukemia.”

Source: WSJ

Share on facebook
Share on telegram
Share on twitter
Share on email